9月底，港交所迎来新一轮医药企业上市申请高峰。经北京商报记者统计，仅在9月29日—30日期间，就有四川好医生云医疗科技集团股份有限公司（以下简 称"好医生"）、安诺优达基因科技（北京）股份有限公司（以下简称"安诺优达"）等11家医药企业集体递交上市申请。值得注意的是，其中包括烟台蓝纳成 生物技术股份有限公司（以下简称"蓝纳成"）在内的多家企业，在申报材料中带有特殊标识"B"，显示其依据港交所第18A章规则申请上市，即尚未盈利的 生物科技公司。此外，本轮递表企业中有多家已在A股上市，如长春高新、百利天恒、贝达药业等。在业内人士看来，"A+H"双平台上市有助于生物医药企 业拓展融资渠道，增强资金实力，从而推动创新药与高端医疗器械的国产化进程，加速产业整体升级。 此轮递表港交所的医药企业涉及诸多细分领域。诸如，9月30日递表港交所的安诺优达，主营业务包括分子诊断为基础的IVD医疗器械和多组学生命科学研 究服务，尤其擅长基于NGS的产前检测IVD产品。其临床测序解决方案涵盖IVD检测试剂盒、基因测序仪及生物信息学分析软件，并提供技术支持和实验室 设计服务。 同样在9月30日递表的好医生是一家综合性基层医疗赋能平台，为 ...

Group 1 - Shein is considering a listing in Hong Kong, which has sparked discussions about its compliance and regulatory challenges in the UK and Europe [1][5][14] - The Hong Kong Stock Exchange (HKEX) has a "Special Technology Companies" listing route, but Shein does not fit the defined criteria for this category [2][4] - Shein's growth has slowed significantly, with projected revenue growth dropping to 19% in 2024 and a nearly 40% decline in net profit [4][15] Group 2 - Shein has faced multiple compliance issues, including a €40 million fine in France for misleading commercial practices, which raises concerns for HKEX [6][8][9] - The company is under investigation for privacy violations and has been accused of using deceptive marketing practices that may infringe on consumer rights [8][9] - Shein's legal troubles extend to intellectual property disputes in both the US and Europe, with numerous lawsuits filed against it [9][10] Group 3 - Shein has been criticized for its "de-China" stance, distancing itself from its Chinese roots to appeal to Western regulators [10][12][13] - The company has been accused of supporting policies that could harm the interests of the Chinese market, which has led to backlash [12][13] - There are concerns that Shein's potential listing could negatively impact the reputation of HKEX due to its ongoing controversies [14] Group 4 - Shein's valuation target of $50 billion is considered inflated, with a more reasonable estimate around $30 billion based on industry standards [15][18] - The company reportedly has $12 billion in cash, indicating it does not have an urgent need for capital, suggesting the listing may primarily benefit existing shareholders [18] - The HKEX's "Special Technology Companies" route is intended for genuine tech firms, and Shein's listing may undermine the integrity of this initiative [18]